Blue Jet Healthcare Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹11,019 Cr
- Book Value
- ₹78.4
- Stock P/E
- 46.9
- Dividend Yield
- 0.21%
- ROE
- 19.9%
- ROCE
- 26.5%
- PEG Ratio
- 3.89
- EV/EBITDA
- 31.5
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Blue Jet Healthcare share price today
Blue Jet Healthcare (NSE: BLUEJET) sells to innovators, not to pharmacies. Its chemistry: contrast-media intermediates (the iodinated molecules behind CT/MRI imaging agents, supplied into the global oligopoly of GE Healthcare, Bracco, Guerbet), saccharin-based sweeteners, and — the story the market watches — intermediates feeding the GLP-1 weight-loss supply chain as those blockbusters scale globally.
Niche chemistry for qualified customers shows up exactly where it should: a 30.6% operating margin, 26.5% ROCE, and near-zero debt. At 46.9×, our universe tags it wait — the contrast-media annuity is proven; the GLP-1 kicker is still being priced on promise.
Qualified-supplier annuities
Contrast-media chemistry is regulated, multi-step and safety-critical — once Blue Jet is validated inside an imaging giant’s supply chain, the relationship persists for product lifetimes. Imaging volumes grow with global healthcare penetration; the customer oligopoly grows with them. The GLP-1 chain adds a second act: high-growth demand for specific intermediates where early qualification compounds into scale contracts. Recent growth (12–14%) understates the pipeline the capex is building for.
Watch-items: GLP-1 contract wins converting to revenue, customer concentration (few, giant clients), capacity commissioning schedules, and the 73.2% promoter holding’s post-IPO stability.
The numbers
From our research universe snapshot (5 Aug 2026):
| Metric | Value |
|---|---|
| Market cap | ₹11,019 Cr |
| P/E (TTM) | 46.9 |
| EV/EBITDA | 31.5 |
| Operating margin | 30.6% |
| ROE / ROCE | 19.9% / 26.5% |
| Debt to equity | 0.03 |
| Sales CAGR (5y) | 13.7% |
| Profit CAGR (5y) | 12.1% |
| Promoter holding | 73.2% |
| EPS (TTM) | ₹12.41 |
Blue Jet Healthcare share price target 2026 to 2030
EPS base ₹12.41 (TTM). Bear: GLP-1 hopes fade, base business only — 8% growth, multiple at 28×. Base: contrast media compounds, GLP-1 contracts land — 14% growth at 38×. Bull: the weight-loss supply chain scales through Blue Jet — 19% growth at 48×.
| Year | Bear (28×, +8%) | Base (38×, +14%) | Bull (48×, +19%) |
|---|---|---|---|
| 2026 | ₹375 | ₹538 | ₹709 |
| 2027 | ₹405 | ₹613 | ₹844 |
| 2028 | ₹438 | ₹699 | ₹1,005 |
| 2029 | ₹473 | ₹796 | ₹1,195 |
| 2030 | ₹511 | ₹908 | ₹1,420 |
From ₹582, the base case is ≈ +56% over four and a half years; the bear is −12%. Annuity chemistry with an optional blockbuster kicker — the range below buys the annuity and takes the kicker free.
Reasons to own Blue Jet Healthcare (at the right price)
- Contrast-media qualification moats — supplier switches are regulatory events.
- The GLP-1 intermediates option on the decade’s biggest drug franchise.
- 31% operating margins prove the chemistry is specialty, not commodity.
- Net-cash balance sheet funds capacity ahead of contracted demand.
- Customer oligopoly (imaging giants) grows structurally with global diagnostics.
The risks: three customers can be most of revenue in any quarter, GLP-1 supply chains are competitive and repricing fast, and 47× already banks part of the kicker.
Should you buy at the current price?
The live buy range below is for members — the annuity’s price, not the story’s.
FAQ
What is the Blue Jet Healthcare share price target for 2030? Base case ≈ ₹908 (38× on 14% compounded growth), bear ≈ ₹511, bull ≈ ₹1,420. Arithmetic above.
What are contrast-media intermediates? The iodinated chemistry inside injectable imaging agents used in CT scans and angiography. A handful of global companies sell the agents; Blue Jet supplies the molecules beneath them.
How real is the GLP-1 opportunity? The demand is real and enormous; the question is share. Blue Jet’s qualification record with innovators is the asset — contract announcements, not projections, are the confirmation to watch.
When are Blue Jet’s next results? Track the exact date on our results calendar.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.